Prasterone vaginal - Bayer/Endoceutics

Drug Profile

Prasterone vaginal - Bayer/Endoceutics

Alternative Names: Dehydroepiandrosterone; DHEA; INTRAROSA; Intravaginal dehydroepiandrosterone; Intravaginal prasterone; Prasterone vaginal ovule; Vaginorm

Latest Information Update: 26 Jul 2017

Price : $50

At a glance

  • Originator Endoceutics
  • Developer AMAG Pharmaceuticals; Endoceutics
  • Class Androstenols; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Testosterone congener stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Dyspareunia
  • Phase III Atrophic vaginitis

Most Recent Events

  • 24 Jul 2017 Launched for Dyspareunia in USA (Vaginal)
  • 04 Apr 2017 Prasterone vaginal licensed to AMAG Pharmaceticals in USA
  • 14 Feb 2017 Endoceutics and AMAG Pharmaceuticals entered into an license agreement to co-promote and co-develop prasterone in USA for Dyspareunia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top